Corbus (CRBP) CMO Nicacio Viana Receives RSUs & Options

What Happened
Nicacio Leonardo Viana, Chief Medical Officer of Corbus Pharmaceuticals (CRBP), received equity awards on August 16, 2026. The filing reports 58,333 restricted stock units (RSUs) granted (settled in common stock) and a separate derivative award covering 191,676 shares. Both awards were granted at $0.00 (no cash paid).

Key Details

• Transaction date: August 16, 2026; Form 4 filed August 17, 2026 (timely).
• Awards: 58,333 RSUs; 191,676-share derivative award (both reported as acquisition, code A). Filing notes the derivative award was made under the issuer’s 2026 Inducement Award Plan.
• Vesting (RSUs): 25% vests on each anniversary beginning Aug 16, 2027 (four-year annual vesting). If the company terminates Viana without cause after the first vesting date, a prorated acceleration applies for the next vesting tranche; unaccelerated RSUs are forfeited upon termination.
• Vesting (derivative/option): 25% of the option vests Aug 3, 2027; remaining 75% vests in equal monthly installments over 36 months beginning Sep 3, 2027.
• Price: $0.00 per share (grant). No proceeds or purchase price reported.
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes: F2 indicates the derivative amount includes the 58,333 unvested RSUs; F3 ties the option award to the 2026 Inducement Award Plan and details its vesting schedule.

Context
These are grant awards (not open-market purchases or sales). Grants are typically compensation/retention tools and do not by themselves indicate buying or selling sentiment. The RSUs will convert to shares only as they vest; the option vesting schedule means the economic benefit is realized over the coming years if Viana remains employed.